首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1562320

2030 年亚太地区人类疫苗佐剂市场预测 - 区域分析 - 按类型、应用（流感、肝炎、人类乳突病毒等）和最终用户

Asia Pacific Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 113 Pages | 订单完成后即时交付

价格

简介目录图表

2022年亚太人用疫苗佐剂市场估值为3.3019亿美元，预计2030年将达到10.0852亿美元；预计2022年至2030年复合年增长率为15.0%。

不断成长的製药业推动亚太地区人类疫苗佐剂市场

不断扩大的製药业预计将对佐剂的需求产生积极影响，因为它们可以提高疫苗的功效和安全性。製药业日益关注传染病、癌症和自体免疫疾病，为开发针对这些特定疾病领域的个人化疫苗和佐剂提供了平台。这为佐剂製造商提供了开发专门佐剂以增强对这些疾病疫苗的免疫反应的机会。根据 EFPIA 的数据，巴西、中国和印度製药业在 2016-2021 年期间分别成长了 11.7%、6.7% 和 11.8%，而排名前五名的欧盟市场和美国市场则录得平均市场成长率分别为5.8 %和5.6%。此外，根据印度品牌资产基金会 (IBEF) 的数据，印度是全球製药业的一个主要且正在崛起的参与者。该国是世界上最大的仿製药贸易国，占全球供应量的近20%。它供应了全球约 50% 的疫苗接种需求。国内製药业包括 3,000 家製药公司和约 10,500 个製造单位。根据印度政府的官方数据，印度医药产业价值近500亿美元，其中超过250亿美元来自出口。印度占世界仿製药出口的 20% 左右。此外，日本是世界上最大的药品市场之一。根据厚生劳动省（MHLW）年度药品生产统计数据，2020 年日本处方药和非处方药市场规模为 1,070 亿美元。随着产业不断发展和创新，对能够支持个人化疫苗开发的佐剂的需求不断增加，推动亚太地区人类疫苗佐剂市场的显着成长和投资。因此，全球不断成长的製药业可能会在未来几年为亚太地区人类疫苗佐剂市场创造利润丰厚的成长机会。

亚太地区人类疫苗佐剂市场概况

中国对医疗保健和製药业进行了大量投资，旨在增强国内生产、研究和开发能力。这一战略重点使该国成为亚太人类疫苗佐剂市场的关键参与者。此外，中国是世界上人口最稠密的国家之一；目前人口约14.1亿。根据2020年10月发布的最新全球疾病负担（GBD）研究显示，该国人口容易罹患各种传染病、慢性和急性疾病。

传染病流行率的增加预计将刺激疫苗接种的需求。根据ICO/IARC资讯中心2023年HPV与癌症资讯中心的报告，中国有5.824亿15岁及以上女性有HPV相关子宫颈癌的风险。据估计，中国普通人群中约有 3.8% 的女性在特定时间携带子宫颈 HPV-16/18 感染，69.1% 的侵袭性子宫颈癌归因于 HPV 16 或 18。推动亚太地区人类疫苗佐剂市场的成长。

亚太地区人类疫苗佐剂市场收入及 2030 年预测（百万美元）

亚太地区人类疫苗佐剂市场区隔

亚太地区人类疫苗佐剂市场按类型、应用、最终用户和国家分类。

根据类型，亚太人疫苗佐剂市场分为颗粒佐剂、乳液佐剂、组合佐剂等。 2022 年，颗粒助剂领域占最大的市场份额。

从应用来看，亚太人用疫苗佐剂市场分为流感、肝炎、人类乳突病毒（HPV）等。 2022 年，流感细分市场占据最大市场。

以最终用户划分，亚太地区人类疫苗佐剂市场分为製药和生技公司、CMO 和 CRO 等。 2022 年，製药和生物技术公司领域占据最大的市场份额。

依国家划分，亚太地区人类疫苗佐剂市场分为日本、中国、印度、澳洲、韩国和亚太其他地区。 2022年，中国在亚太地区人类疫苗佐剂市场份额中占据主导地位。

Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Hawaii Biotech Inc、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是亚太地区人类疫苗佐剂市场上的一些领先公司。

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases. According to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion. As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the Asia Pacific human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the Asia Pacific human vaccine adjuvants market in the coming years.

Asia Pacific Human Vaccine Adjuvants Market Overview

China has invested heavily in its healthcare and pharmaceutical industries, aiming to bolster domestic production, research, and development capabilities. This strategic focus has positioned the country as a key player in the Asia Pacific human vaccine adjuvants market. Additionally, China is among the most densely populated countries in the world; the current population is ~1.41 billion. According to the latest Global Burden of Disease (GBD) study published in October 2020, the population in the country is prone to various infectious, chronic, and acute diseases.

An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. According to a report by the ICO/IARC Information Centre on HPV and Cancer in 2023, China has a population of 582.4 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. About 3.8% of women in China in the general population are estimated to harbor cervical HPV-16/18 infection at a given time, and 69.1% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the rising number of patients and the increasing demand for vaccines for treatment are also expected to boost the Asia Pacific human vaccine adjuvants market growth.

Asia Pacific Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Human Vaccine Adjuvants Market Segmentation

The Asia Pacific human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Asia Pacific human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Asia Pacific human vaccine adjuvants market is categorized into influenza, hepatitis, Human Papilloma Virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Asia Pacific human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Asia Pacific human vaccine adjuvants market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific human vaccine adjuvants market share in 2022.

Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Asia Pacific Market Analysis

5.1 Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Asia Pacific Human Vaccine Adjuvants Market Forecast Analysis

6. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human papilloma virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Human Vaccine Adjuvants Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 China Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 China Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 China Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Japan Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 Japan Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 Japan Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 India Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 India Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 India Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Australia Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Australia Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Australia Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.5 South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 South Korea Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.5.2 South Korea Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.5.3 South Korea Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.6 Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.6.2 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.6.3 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hawaii Biotech Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Croda International Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Novavax Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Phibro Animal Health Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation
Table 2. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human Papilloma Virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)